Fulgent Genetics Stock News

Key Prominent Players Covered in the US Genetic Testing Market are Invitae Corporation (San Francisco, U.S.), Ambry Genetics (Aliso Viejo, U.S.), BioReference Laboratories, Inc. (Elmwood Park, U.S.), Progenity, Inc. (San Diego, U.S.), Quest Diagnostics Incorporated (Secaucus, U.S.), Myriad Genetics, Inc. (Salt Lake City, U.S.), Fulgent Genetics (Temple City, U.S.), Burning Rock Biotech Limited (Guangzhou, China) Key Prominent Players Covered in the US Genetic Testing Market are Invitae Corporation (San Francisco, U.S.), Ambry Genetics (Aliso Viejo, U.S.), BioReference Laboratories, Inc. (Elmwood Park, U.S.), Progenity, Inc. (San Diego, U.S.), Quest Diagnostics Incorporated (Secaucus, U.S.), Myriad Genetics, Inc. (Salt Lake City, U.S.), Fulgent Genetics (Temple City, U.S.), Burning Rock Biotech Limited (Guangzhou, China)

BLDR, FLGT, MRBK, CC, and NMRK have been added to the Zacks Rank #1 (Strong Buy) List on November 11th.

Fulgent Shares Are Still Very Attractive

Fulgent Genetics Inc (NASDAQ: FLGT) reported Q3 sales of $227.9 million, +124% Y/Y, beating the consensus of $264 million primarily driven by sales of its COVID-19 tests. Fulgent said that the billa

Fulgent Genetics, Inc. (FLGT) CEO Ming Hsieh on Q3 2021 Results - Earnings Call Transcript

The genomic revolution is upon us and these stocks could be great vehicles for investors who want to take advantage of it.

Fulgent's recent quarters have featured staggering revenue growth, but there's more under the surface. The core genetic testing business is the driver of future growth.

The company is leveraging success with its COVID-19 tests to position itself better for a post-pandemic world.

An investment in one or both of these high-growth companies could generate stellar returns.

Fulgent has capitalized on COVID-19 testing, but even though this segment of its business might slow, there are plenty of reasons to own the company.

TEMPLE CITY, Calif.--(BUSINESS WIRE)---- $FLGT--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient c

The pandemic isn't over yet.

Everyone loves a discount.

ACCD, CHRS, ELVT, FLGT, and GSHD have been added to the Zacks Rank #5 (Strong Sell) List on August 17, 2021.

Spectacular quarterly results were not enough to satisfy investors' appetites.